comparemela.com

Latest Breaking News On - Astellas venture management - Page 5 : comparemela.com

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics.

United statesSan franciscoRui zhangBristol myers squibbPharmaceuticals china co ltdChina national medical products administrationCompany clinical trial applicationPharmaceuticals incOsage university partnersMultiple myelomaClinical trial applicationRecommended phaseChief executive officerCleave therapeuticsMarcus venturesAstellas venture management

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

MaxCyte's Flow Electroporation® and ExPERT technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md, Jan. 3, 2023 /PRNewswire/

Doug doerflerPrnewswire maxcyte incSv health investorsCatamaran bio incFlow electroporationCatamaran bioSofinnova partnersLightstone venturesTakeda venturesAstellas venture management

Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio

/PRNewswire/ Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc..

San franciscoUnited statesSan carlosKenji yasukawaStevenr deitcherCellinfinity bioPremal patelDouglas crawfordWilliam wattPrnewswire astellas venture managementAstellas pharma incAstellas venture managementMission biocapital biolabsMission biocapitalBoth companieswinAstellas pharma

Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio

/PRNewswire/ Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc..

San franciscoUnited statesSan carlosKenji yasukawaStevenr deitcherCellinfinity bioPremal patelDouglas crawfordWilliam wattPrnewswire astellas venture managementAstellas pharma incAstellas venture managementMission biocapital biolabsMission biocapitalBoth companieswinAstellas pharma

Casma Therapeutics Raises $46.0M in Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomKeith dionneHiromichi kimuraEisai coAmgen venturesColumn groupCasma therapeuticsAstellas venture managementEuclidean capitalMirae assetOno venture investmentEventide asset managementSchroders capitalThird rockInvestment directorAstellas ventures

vimarsana © 2020. All Rights Reserved.